Termination by Triangle Clause Samples
The 'Termination by Triangle' clause grants the party identified as Triangle the explicit right to end the agreement under specified conditions. In practice, this clause outlines the procedures Triangle must follow to exercise this right, such as providing written notice or adhering to a notice period, and may detail any obligations or consequences that arise upon termination, like payment of outstanding fees or return of property. Its core function is to provide Triangle with a clear and structured mechanism to exit the contract, thereby managing risk and ensuring both parties understand the process and implications of early termination initiated by Triangle.
POPULAR SAMPLE Copied 1 times
Termination by Triangle. Triangle shall have the right to terminate this Agreement in the entire Territory or one or more countries of the Territory (without affecting this Agreement in the remaining countries of the Territory), by giving Bukwang sixty (60) days’ prior written notice thereof.
Termination by Triangle. Triangle shall have the right to terminate this Agreement by giving Dynavax sixty (60) days' prior written notice thereof. Such termination may be made with respect to one or more: (a) countries of the Territory; or (b) form of Licensed Product in respect of the treatment of HBV, without affecting this Agreement in respect of other countries or forms of Licensed Products.
Termination by Triangle. Triangle shall have the right to terminate this Agreement in the entire Territory or one or more countries of the Territory (without affecting this Agreement in the remaining countries of the Territory), by giving Mitsubishi *** prior written notice thereof. Triangle shall base any decision to terminate pursuant to this Section 11.3 on the determination that the scientific, regulatory and/or commercial profile of the Licensed Product in the country or countries in question does not justify continued development or marketing of the Licensed Product using the same standard Triangle would use in assessing whether to continue the development or marketing of its other HIV products having a comparable scientific, regulatory and commercial profiles.